BAP1 and neoplasm: Previous analyses of tumors and blood from the PEMDAC trial suggested that genetics (BAP1 status or a UV mutational signature), tumor burden (levels of ctDNA and LDH), and immune cell distribution (T cells, monocytes, and neutrophils) were associated with responses and survival (24).